← Leaderboards
Stefano Rivella
Weill Medical College Of Cornell Univ
$10,978,618
Attributed
$15,336,132
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,336,132 · 7
By mechanism
R01$13,886,316 · 4
R21$782,760 · 2
K01$667,056 · 1
Top collaborators
- Robert E Fleming8 shared
- Tomas Ganz5 shared
- Yelena Ginzburg4 shared
Others in their field
Top investigators on “Anemia”
- Russell E Ware · Duke University$48,435,687
- Michael Rutledge Debaun · Vanderbilt University Medical Center$38,268,866
- Peter J. Snyder · University Of Pennsylvania$35,309,252
- Jeffrey Lee Carson · Univ Of Med/Dent Nj-R W Johnson Med Sch$29,495,757
- Michael L. Terrin · Clinical Trials And Surveys Corporation$26,727,584
- Leonard I Zon · Children'S Hospital Boston$26,660,149
Research focus
AnemiaAffectErythropoiesisCellsProductionMediatingBeta ThalassemiaIronIron MetabolismHepcidinKnock-OutHemoglobin Concentration ResultInsightIron OverloadNovel TherapeuticsPhenotypeMouse ModelTissuesLiverErythroid CellsFunctional DisorderBaseHepatocyteErythropoietin
Grant awards (38)
Regulatory Role of Transferrin in Erythropoiesis and Iron Metabolism$706,633
R01 · FY2025 · DK
Development and validation of novel mouse models and expression vectors for characterizing severe alpha-thalassemia pathophysiology and evaluating gene therapy approaches.$607,388
R01 · FY2025 · DK · contact PI
Regulatory Role of Transferrin in Erythropoiesis and Iron Metabolism$679,795
R01 · FY2024 · DK
Development and validation of novel mouse models and expression vectors for characterizing severe alpha-thalassemia pathophysiology and evaluating gene therapy approaches.$580,084
R01 · FY2024 · DK · contact PI
Development and validation of novel mouse models and expression vectors for characterizing severe alpha-thalassemia pathophysiology and evaluating gene therapy approaches.$135,394
R01 · FY2024 · DK · contact PI
Regulatory Role of Transferrin in Erythropoiesis and Iron Metabolism$708,121
R01 · FY2023 · DK
Development and validation of novel mouse models and expression vectors for characterizing severe alpha-thalassemia pathophysiology and evaluating gene therapy approaches.$604,255
R01 · FY2023 · DK · contact PI
Regulatory Role of Transferrin in Erythropoiesis and Iron Metabolism$736,843
R01 · FY2022 · DK
Activin signaling in normal and disordered erythropoiesis$521,104
R01 · FY2021 · DK · contact PI
Activin signaling in normal and disordered erythropoiesis$378,000
R01 · FY2020 · DK · contact PI
Activin signaling in normal and disordered erythropoiesis$83,478
R01 · FY2020 · DK · contact PI
Activin signaling in normal and disordered erythropoiesis$378,000
R01 · FY2019 · DK · contact PI
Activin signaling in normal and disordered erythropoiesis$378,000
R01 · FY2018 · DK · contact PI
Activin signaling in normal and disordered erythropoiesis$378,000
R01 · FY2017 · DK · contact PI
Regulatory Role of Transferrin in Erythropoiesis and Iron Metabolism$408,310
R01 · FY2015 · DK
Hepcidin therapy for iron overload and hematologic disorders$553,241
R01 · FY2014 · DK · contact PI
The influence of genotype on the outcome of gene transfer in beta-thalassemia$409,910
R01 · FY2014 · HL · contact PI
Regulatory Role of Transferrin in Erythropoiesis and Iron Metabolism$409,250
R01 · FY2014 · DK
Hepcidin therapy for iron overload and hematologic disorders$553,380
R01 · FY2013 · DK · contact PI
The influence of genotype on the outcome of gene transfer in beta-thalassemia$398,198
R01 · FY2013 · HL · contact PI
Regulatory Role of Transferrin in Erythropoiesis and Iron Metabolism$394,926
R01 · FY2013 · DK
Regulatory Role of Transferrin in Erythropoiesis and Iron Metabolism$624,498
R01 · FY2012 · DK
Hepcidin therapy for iron overload and hematologic disorders$594,013
R01 · FY2012 · DK · contact PI
The influence of genotype on the outcome of gene transfer in beta-thalassemia$418,275
R01 · FY2012 · HL · contact PI
Hepcidin therapy for iron overload and hematologic disorders$614,637
R01 · FY2011 · DK · contact PI
The influence of genotype on the outcome of gene transfer in beta-thalassemia$422,500
R01 · FY2011 · HL · contact PI
Hepcidin therapy for iron overload and hematologic disorders$787,583
R01 · FY2010 · DK · contact PI
The influence of genotype on the outcome of gene transfer in beta-thalassemia$422,500
R01 · FY2010 · HL · contact PI
Gene therapy for Cooley's anemia in a new mouse model$54,000
K01 · FY2010 · DK · contact PI
The role of hepcidin in beta-thalassemia$246,960
R21 · FY2008 · DK · contact PI
Gene therapy for Cooley's anemia in a new mouse model$129,133
K01 · FY2008 · DK · contact PI
The role of hepcidin in beta-thalassemia$210,000
R21 · FY2007 · DK · contact PI
Gene therapy for Cooley's anemia in a new mouse model$125,188
K01 · FY2007 · DK · contact PI
Gene therapy for Cooley's anemia in a new mouse model$122,327
K01 · FY2006 · DK · contact PI
Identification of Genes Involved in beta- Thelassemia$168,000
R21 · FY2005 · DK
Gene therapy for Cooley's anemia in a new mouse model$119,552
K01 · FY2005 · DK
Identification of Genes Involved in Beta- Thalassemia$157,800
R21 · FY2004 · DK
Gene therapy for Cooley's anemia in a new mouse model$116,856
K01 · FY2004 · DK